The efficacy seen with this combination, particularly in TP53-mutant AML, led to the ongoing randomized phase 3 ENHANCE-2 trial comparing magrolimab plus azacitidine to the physician’s choice of venetoclax plus azacitidine or 7 + 3 chemotherapy in untreated TP53-mutant AML (NCT04778397) [74]. This evidence concerns the gene TP53 and acute myeloid leukemia.